The health claim recognizes the strain’s ability to support healthy bowel habits in adults with irritable bowel syndrome (IBS) at a daily dose of 10 billion colony-forming units (CFU).
Lallemand Health Solutions (Montreal, CA) reports that its probiotic strain L. paracasei HA-196 has been approved for a new health claim in Canada. The health claim recognizes the strain’s ability to support healthy bowel habits in adults with irritable bowel syndrome (IBS) at a daily dose of 10 billion colony-forming units (CFU).
A 2020 randomized, double-blind, placebo-controlled study1 in 251 North American Adults showed that after eight weeks of supplementation, L. paracasei HA-196 reduced frequency of bowel movements in those with IBS-D (diarrhea), increased bowl frequency in those with IBS-C (constipation), and supported quality of life in IBS subjects, including supporting emotional well-being and social functioning.
The company reports that IBS affects approximately 10%-15% of the global population, according to estimates from the International Foundation for Functional Gastrointestinal Disorders.
Reference
Yili to pilot Xampla’s microscopic natural biopolymer capsules for nutrient fortification
July 17th 2024Xampla, a manufacturer natural biopolymers, has announced a partnership with Yili Innovation Centre Europe to test and validate Xampla’s microscopic natural biopolymer capsules used to fortify a range of products with vitamins and nutrients.